eFFECTOR Therapeutics- Warrants (26/08/2026) Accounts Payable

As of the most recent data (March 2026), EFTRW shows a accounts payable of $120K. That compares with $37K in the prior-year period — up 227.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EFTRW's accounts payable is now $120K (was $37K) — a 227.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether eFFECTOR Therapeutics- Warrants (26/08/2026) is outperforming or lagging.

Tracking EFTRW's accounts payable over time shows whether eFFECTOR Therapeutics- Warrants (26/08/2026) is scaling, shrinking, or reshaping that part of the business. The current reading is $120K That compares with $37K in the prior-year period — up 227.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has eFFECTOR Therapeutics- Warrants (26/08/2026)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $120K) with ownership activity and broader fundamentals.

eFFECTOR Therapeutics- Warrants (26/08/2026)'s accounts payable is $120K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.